Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
The First School of Medicine, School of Information and Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
J Cachexia Sarcopenia Muscle. 2022 Oct;13(5):2383-2392. doi: 10.1002/jcsm.13040. Epub 2022 Jul 19.
Previous studies have indicated that sarcopenia is associated with poor post-operative outcomes in liver cancer patients, but the studies are limited by confounding from mixed diseases, retrospective data, and non-standardized measurement methods. At present, there is no research with both muscle mass and strength as predictors for hepatocellular carcinoma (HCC) outcomes. We studied the impact of sarcopenia on post-operative outcomes in HCC patients in a cohort study designed according to the European Working Group on Sarcopenia in Older People standards.
A total of 781 consecutive patients admitted to our centre were registered from May 2020 to August 2021. All participants submitted questionnaires and underwent handgrip strength, chair stand test, physical performance, and computed tomographic evaluation. Then, they were divided into three groups according to muscle mass and strength: Group A (reduced muscle mass and strength), Group B (reduced muscle strength or reduced muscle mass), and Group C (normal muscle mass and strength). The baseline data and post-operative outcomes were compared and analysed. The primary outcome variable in this study was the presence of a major post-operative complication, and the secondary outcome was the 90-day re-admission rate.
A total of 155 patients [median age, 60.00 (IQR, 51.00-66.00) years; 20 females (12.90%)] were included after strict exclusion. The mean (SD) BMI was 23.37 ± 0.23 kg/m . The mean (SD) SMI of all participants was 47.05 ± 0.79 cm /m , and the mean (SD) handgrip strength was 32.84 ± 0.69 kg. Among them, 77 (49.68%) patients underwent laparoscopic hepatectomy, and 73 (47.10%) patients received major hepatectomy. Regarding the post-operative results, Group A had a higher rate of major complications [40.91% (9 of 22) vs. 11.94% (8 of 67) in Group B and 6.06 (4 of 66) in Group C; P = 0.001], higher rate of blood transfusion (77.27% vs. 46.27% in Group B and 42.42% in Group C; P = 0.015), higher hospitalization expenses (P = 0.001), and longer hospital stay (P < 0.001). There was no difference in 90-day re-admission rates among the three groups. Sarcopenia (hazard ratio, 10.735; 95% CI, 2.547-45.244; P = 0.001) and open surgery (hazard ratio, 4.528; 95% CI, 1.425-14.387; P = 0.010) were independent risk factors associated with major complications.
Sarcopenia is associated with adverse outcomes after liver resection for HCC. It should be evaluated upon admission to classify high-risk patients and reduce the risk of major complications.
之前的研究表明,肌少症与肝癌患者术后预后不良有关,但这些研究受到混杂因素的限制,包括混合疾病、回顾性数据和非标准化的测量方法。目前,还没有研究将肌肉质量和力量作为预测肝细胞癌(HCC)结果的指标。我们根据欧洲老年人肌少症工作组的标准,在一项队列研究中研究了肌少症对 HCC 患者术后结果的影响。
本研究共纳入 2020 年 5 月至 2021 年 8 月期间我院收治的 781 例连续患者。所有参与者均提交了问卷,并接受了握力、椅站测试、体能和计算机断层扫描评估。然后,他们根据肌肉质量和力量分为三组:A 组(肌肉质量和力量降低)、B 组(肌肉力量降低或肌肉质量降低)和 C 组(肌肉质量和力量正常)。比较并分析了基线数据和术后结果。本研究的主要结局变量是存在主要术后并发症,次要结局是 90 天再入院率。
严格排除后,共纳入 155 例患者[中位年龄 60.00(IQR 51.00-66.00)岁;女性 20 例(12.90%)]。平均(SD)BMI 为 23.37±0.23kg/m2。所有参与者的平均(SD)SMI 为 47.05±0.79cm/m2,平均(SD)握力为 32.84±0.69kg。其中 77 例(49.68%)患者行腹腔镜肝切除术,73 例(47.10%)患者行肝大部切除术。关于术后结果,A 组主要并发症发生率较高[40.91%(9/22)比 B 组 11.94%(8/67)和 C 组 6.06%(4/66);P=0.001],输血率较高(77.27%比 B 组 46.27%和 C 组 42.42%;P=0.015),住院费用较高(P=0.001),住院时间较长(P<0.001)。三组 90 天再入院率无差异。肌少症(风险比,10.735;95%CI,2.547-45.244;P=0.001)和开放手术(风险比,4.528;95%CI,1.425-14.387;P=0.010)是与主要并发症相关的独立危险因素。
肌少症与 HCC 肝切除术后不良预后有关。入院时应评估肌少症,以对高危患者进行分类,降低主要并发症的风险。